Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.
You may also be interested in...
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
GlaxoSmithKline’s Votrient Recommended For Renal Cell Carcinoma in Draft NICE Appraisal
U.K. will receive a rebate if Votrient does not match Pfizer's Sutent in a current head-to-head trial.